Circulating Transcription Factor Analysis for Early Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting cancer are often invasive, unreliable, and fail to detect the disease at early stages due to non-specific symptoms and low clinical accuracy of existing biomarkers, necessitating a more effective and minimally invasive approach for early cancer detection.
Innovation Solution
A method involving the detection of circulating cell-free chromatin fragments containing transcription factors in body fluids, using a binding agent to isolate and measure DNA fragments associated with these factors, which serves as an indicator of disease presence and tissue origin, enabling non-invasive or minimally invasive cancer detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cancer detection methods (tissue biopsy, imaging) are used, then diagnostic accuracy can be achieved, but the procedure becomes invasive and complex
Solution Approach 1:
The invention extracts and measures circulating chromatin fragments containing transcription factors from blood samples. By isolating these specific DNA fragments that carry tissue-specific transcription factor signatures, the method obtains diagnostic information without performing invasive tissue biopsy procedures, thus resolving the contradiction between diagnostic accuracy and procedural invasiveness
Solution Approach 2:
The invention uses circulating chromatin fragments as an intermediary biomarker that carries information from tumor tissue to blood circulation. These fragments serve as a mediator that allows distant sampling of tumor-specific information through simple blood draws, eliminating the need for direct tissue access while maintaining diagnostic reliability
2Ease of operation
If traditional biomarkers (CEA, AFP, CA125, PSA) are used for cancer screening, then the tests are simple and routine, but the clinical accuracy is too low for reliable diagnosis
Solution Approach 1:
The invention changes the measured parameter from traditional protein biomarkers to circulating chromatin fragments containing transcription factors. This parameter change enables the use of simple blood-based testing while achieving high clinical accuracy, as the chromatin fragments carry unique transcription factor signatures specific to different tissue types and cancer states
Solution Approach 2:
The invention measures composite biomarkers consisting of DNA fragments bound to transcription factors. This composite structure combines the stability and detectability of DNA with the tissue-specific information carried by transcription factors, achieving both simplicity of measurement and high diagnostic accuracy
3Productivity
If cancer is detected using existing biomarkers, then routine screening can be performed, but the detection occurs at late stages when treatment is difficult
Solution Approach 1:
The invention replaces the mechanical approach of tissue biopsy with a biochemical assay measuring circulating chromatin fragments. This substitution enables high-throughput screening of blood samples while detecting early-stage cancer through the presence of tumor-derived chromatin fragments, achieving both high productivity and early detection capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides superior analytical and clinical specificity and sensitivity for cancer detection, allowing for early-stage cancer identification and monitoring without the need for invasive tissue biopsies, with potential applicability to various cancer types.
Implementation Method 1
contacting the body fluid sample with a binding agent which binds to the transcription factor
Data Source
AI summary
The invention relates to methods for detecting disease in a subject by means of a minimally invasive body fluid test for the detection of circulating chromatin fragments that include a transcription factor and associated DNA sequence as an indicator of the presence of disease in the subject, e.g. cancer. The methods may comprise sequencing the associated DNA sequence and/or removing cell free nucleosomes from the body fluid.